Lupus & antiphospholipid syndrome
Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA
Authors' conclusion
Despite increasing availability of alternative treatment options, patients with SLE in the USA increasingly rely on glucocorticoid-based therapy.
Study context
- Population
- Adults with SLE in the USA, OptumLabs Data Warehouse, 2007–2023 (mean age 51.2 years; 89% female)
- Participants
- 19,122 adults
- Outcome
- Annual prevalent and incident use of antimalarials, GC and immunosuppressive medications, trends over time
Main finding
As reported in the abstract
Treatment use trends, 2007–2023
- Prevalent antimalarial users decreased, 79.4% in 2007 to 77.2% in 2023
- p=0.0055
- Incident antimalarial users fluctuated, lowest 5.8% in 2021, highest 8.1% in 2008
- p=0.008
- Prevalent GC users increased, 64.6% in 2007 to 66.7% in 2023
- p=0.0132
- Incident GC users increased, 12.4% in 2007 to 21.7% in 2023
- p<0.0001
- CYC use decreased, 2.0% in 2007 to 0.4% in 2023
- p<0.0001
- MMF use increased, 7.7% in 2007 to 10.3% in 2023
- p<0.0001
- RTX use increased, 1.4% in 2007 to 2.1% in 2023
- p<0.0001
- Belimumab use increased, 0.8% in 2011 to 6.1% in 2023
- p=0.0001
Observational data: associations, not effects.
Original publication
Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA. Lupus Sci Med. Published 9 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →